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Drug resistance in malaria and in tuberculosis (TB) are 
major global health problems. Although the terms multidrug-
resistant TB and extensively drug-resistant TB are precisely 
defi ned, the term multidrug resistance is often loosely used 
when discussing malaria. Recent declines in the clinical 
effectiveness of antimalarial drugs, including artemisinin-
based combination therapy, have prompted the need to 
revise the defi nitions of and/or to recategorize antimalarial 
drug resistance to include extensively drug-resistant ma-
laria. Applying precise case defi nitions to different levels of 
drug resistance in malaria and TB is useful for individual 
patient care and for public health.
Malaria and tuberculosis (TB) are 2 of the most com-mon infectious diseases in resource-limited coun-
tries. Each year, >1.7 million persons die of TB (1) and 
almost 1 million die of malaria (2). For each disease, emer-
gence of resistance to common fi rst-line therapies has been 
a major challenge to disease control. Drug resistance in TB 
and malaria arises from inadequate or inappropriate use 
of antimicrobial agents; however, the defi nitions used to 
classify drug resistance, as well as the public health con-
trol measures, vary. These differences sometimes lead to 
confusion and misinterpretation by those unfamiliar with 
either or both diseases. This confusion is compounded by 
the fact that each pathogen is increasingly resistant to more 
drugs, and new descriptive terms such as multidrug resis-
tant (MDR) and, for TB, extensively drug-resistant (XDR) 
have been introduced to describe these changes. For TB, 
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PERSPECTIVE
defi nitions of these new terms are now widely accepted. 
For malaria, recent changes in clinical effectiveness of an-
timalarial drugs, in particular the emergence of artemisinin 
resistance, are forcing malaria experts to consider revising 
the defi nitions of drug resistance for Plasmodium falcipar-
um. Without clear defi nitions, prioritization of resources to 
treat and control malaria will be diffi cult.
Categories of Drug Resistance
Tuberculosis
Drug-resistant TB was identifi ed shortly after the fi rst 
anti-TB drugs were introduced in the 1940s (3); the term 
refers to TB strains resistant to at least 1 anti-TB drug, usu-
ally determined by in vitro phenotypic methods (e.g., my-
cobacterial culture). Globally, resistance to a single anti-
TB drug is the most common pattern of drug resistance. 
Recognition of the relatively rapid onset of resistance to 
anti-TB monotherapy, usually within months, led to the de-
velopment of multidrug therapy as the standard of care in 
the 1960s (4).
Although TB can be treated with many drugs and a 
strain of TB can be resistant to any or all of these, an in-
ternational consensus evolved to defi ne MDR TB as resis-
tance to at least isoniazid and rifampin. Resistance to other 
anti-TB drugs, without resistance to both isoniazid and 
rifampin, is defi ned as polydrug resistance. This consen-
sus defi nition of what level of resistance constitutes MDR 
was based on data showing that anti-TB chemotherapy was 
most likely to fail if the TB strain was resistant to isoniazid 
and rifampin at the beginning of treatment (5). The recog-
nition that MDR strains further evolved with resistance to 
a selected group of reserve, or second-line, anti-TB drugs 
led to creation of the term XDR TB in 2006 (6). The defi ni-
tion of XDR TB is resistance to isoniazid and rifampin plus 
resistance to any fl uoroquinolone and at least 1 of the 3 in-
jectable second-line drugs used in TB treatment (amikacin, 
kanamicin, or capreomycin) (7).
Malaria
Although the decreased sensitivity of malaria parasites 
to an antimalarial drug was fi rst reported about a century 
ago in association with quinine, the term drug-resistant ma-
laria was rarely used; resistance was not considered a major 
problem until the late 1950s, after chloroquine resistance 
emerged. Historically, chloroquine was widely used as the 
standard fi rst-line drug against P. falciparum. Resistance 
was fi rst detected on the Thailand–Cambodia and the Ven-
ezuela–Colombia borders, near areas where chloroquinated 
salt was used for malaria control, forcing the affected coun-
tries to begin switching to sulfadoxine–pyrimethamine (SP) 
in the 1970s. Resistance to SP developed quickly, again on 
the Thailand–Cambodia border. The spread of chloroquine 
and SP resistance to other parts of Asia and as far as Africa 
is well documented (8). A review of the development of 
drug-resistant malaria is available elsewhere (9). Only drug 
resistance in P. falciparum will be discussed in this article.
 The term drug-resistant malaria originally referred to 
P. falciparum strains resistant to chloroquine, SP, or both. 
Multidrug resistance of P. falciparum is strictly defi ned as 
resistance to >2 antimalarial compounds of different chem-
ical classes, recommended by the National Malaria Control 
Program (NMCP) (10). The Thailand–Cambodia border 
was the fi rst area to be recognized as a multidrug resistant 
zone because of the successive failure of chloroquine, SP, 
and then mefl oquine in the late 1980s. These antimalarial 
drugs belong to different chemical classes; all were des-
ignated as the fi rst-line drugs against falciparum malaria 
by the Thai NMCP and were also used by the Cambodian 
NMCP.
Relationship between Drug 
Resistance and Treatment
For new cases of TB, treatment is usually a 4-drug reg-
imen of isoniazid, rifampin, pyrazinamide, and ethambutol 
for 2 months (intensive phase), followed by 4–6 months 
of only isoniazid and rifampin or isoniazid and ethambu-
tol (continuation phase). The duration of this standardized 
regimen may vary, depending on a number of factors, in-
cluding economic considerations and availability of cul-
ture-based diagnosis and monitoring. For example, United 
States guidelines, in contrast to those of most resource-con-
strained and developing countries, emphasize mycobacte-
rial culture for TB diagnosis and recommend extending TB 
treatment for patients with cavities visible on chest radio-
graph and persistence of positive sputum cultures after 2 
months of treatment.
To prevent inadequate drug ingestion and thereby resis-
tance, staff in TB programs often directly observe patients 
ingesting their medications. Because directly observed ther-
apy requires substantial human resources, the World Health 
Organization (WHO) recommends that directly observed 
therapy should be used any time that rifampin is adminis-
tered. Many countries began using a combination of iso-
niazid and ethambutol, rather than isoniazid and rifampin, 
in the continuation phase, because of the cost of rifampin 
and an inability to provide directly observed therapy for the 
entire duration of this phase. The most common reason to 
vary the treatment regimen is documented drug resistance 
or a history of previous TB treatment, which is a risk factor 
for resistance development. In most developing countries, 
drug resistance data are sparse because confi rmation of in-
fection with Mycobacterium tuberculosis followed by drug 
susceptibility testing requires use of advanced molecular 
diagnostics and/or slower and more laborious culture meth-
ods. Therefore, patients are usually treated on the assump-
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tion that they are infected with a drug-susceptible strain. 
The drug regimen is usually changed only if the patient’s 
condition does not clinically improve, including having 
persistently positive sputum smears, after months of treat-
ment. Retreatment protocols in most countries require pro-
longed therapy with essentially the same basic drugs before 
the patient is eligible to receive a drug regimen containing 
second-line drugs specifi cally for treatment of MDR TB.
Although multidrug regimens to prevent and treat drug-
resistant TB were fi rst evaluated in the 1950s, use of true 
combination therapy for malaria, the simultaneous use of 
>2 drugs (with independent modes of action and different 
chemical targets) to kill asexual blood-stage parasites, did 
not arise until much later. However, during the past decade, 
combination therapy has become the norm, intended to im-
prove effectiveness and reduce the spread of resistance.
In uncomplicated malaria, an outpatient is usually 
treated with the fi rst-line antimalarial drugs recommended 
by the local health authority for the malaria-endemic re-
gion in which the patient became infected. For example, 
a patient infected with P. falciparum on the eastern Thai-
land–Laos border would be treated with an artesunate–
mefl oquine combination plus primaquine at a government 
malaria clinic on the Thailand side of the border, or with an 
artemether–lumefantrine combination (Coartem; Novartis 
AG, Basel, Switzerland) on the Laos side of the border. For 
travelers returning to their home country outside a malaria-
endemic area, different drugs may be prescribed. In none 
of these situations would a physician expect any labora-
tory tests to determine drug susceptibility before making 
a treatment decision. As an acute, potentially fatal disease, 
falciparum malaria requires effective treatment promptly.
For malaria, the geographic location in which infec-
tion is acquired is the primary determinant of the risk for 
a drug-resistant infection. Unlike MDR TB, the decision 
to treat and the treatment of MDR malaria do not require 
complex clinical and laboratory assessment of an individual 
patient’s isolate, except for severe malaria, which requires 
critical care capacity. For TB, the geographic area in which 
infection is acquired is not as reliable a determinant of the 
treatment choice. Despite wide differences in MDR TB 
prevalence across countries, the most reliable predictors of 
MDR risk for a TB patient are a history of prior treatment 
or known exposure to another case-patient (i.e., contact 
with an index MDR TB case-patient), not geography (11).
Public Health Implications
Knowing the drug susceptibility pattern of a TB strain 
or whether a malaria infection was acquired in a specifi c 
malaria-endemic area helps not only with therapeutic de-
cision making but also with predicting the patient’s prog-
nosis. From the public health perspective, information on 
drug resistance is useful for strategic planning.
The proportion of TB case-patients infected with MDR 
strains, when stratifi ed by previous treatment status, helps 
public health offi cials evaluate the intensity of community 
transmission and the strength of the TB program in curing 
patients. Unfortunately, the absence of continuous, system-
atic, representative, and timely drug susceptibility data, es-
pecially for second-line anti-TB drugs, is a major obstacle 
for the control of drug-resistant TB. Consequently, a large 
number of infectious MDR- and XDR TB cases globally 
may go undiagnosed.
For malaria, the level of drug resistance in a specifi c 
disease-endemic area is usually judged by in vivo thera-
peutic effi cacy monitoring and in vitro drug susceptibility 
assays of malaria-infected blood specimens (12). To de-
termine the trend of drug effi cacy over years, each method 
requires sentinel sites, specially trained staff, and sustained 
efforts backed by steady public health policy. In fact, the 
simplest way to monitor the clinical effi cacy of a given rou-
tine therapeutic regimen against the parasite is universal, 
comprehensive, posttherapeutic follow-up of the patients for 
28–42 days. Such a procedure would draw early attention to 
the possibility of specifi c drug resistance, thus prompting 
appropriate investigations to avoid any possible delay in the 
confi rmation of resistance; delay is an inherent shortcoming 
when observations are restricted to programmatic effi cacy 
surveillance studies. Unfortunately, in practice this monitor-
ing is sometimes diffi cult to achieve among some popula-
tions, such as mobile migrant populations, who are at high 
risk along many international borders.
Application of molecular surveys can also be useful 
for identifying regions at risk for emergence of antimalarial 
drug resistance and alerting program management of the 
need to conduct in-depth studies, thus allowing suffi cient 
time for consideration of drug policy change (8,13). The 
availability of molecular markers for more drugs, markers 
with improved accuracy, improvement in the ease of assays, 
and the lowering of assay-associated costs will enhance the 
usefulness of molecular mapping of drug resistance.
For TB, the term XDR was created to describe not only 
TB strains that are resistant to more of the available drugs 
but also infections that are substantially more diffi cult to 
cure. For example, for patients co-infected with HIV, XDR 
TB is often fatal (11). An equivalent term for malaria does 
not yet exist, although infections with similar characteris-
tics—resistance developed successively to more drugs and 
the lack of alternative drug choices—will represent identi-
cal challenges to control programs.
When the term MDR malaria was fi rst introduced 2 
decades ago, it was intended to describe resistance to new 
drug groups other than the common, standard antimalarial 
drugs used at that time, namely, chloroquine (a 4-amino-
quinoline) and SP (antifolates). The term was fi rst applied 
to the Thailand–Cambodia border after the emergence of 
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mefl oquine resistance. Artemisinin was introduced, in the 
form of artemisinin-based combination therapy (ACT), as 
a replacement for mefl oquine monotherapy. Artesunate–
mefl oquine became the fi rst ACT to be used for the control 
of MDR malaria. It was adopted as the fi rst-line therapy 
for falciparum malaria by the Thai NMCP in 1995 and the 
Cambodian NMCP in 2000. The rapid antimalarial activity 
of artemisinin compounds means that they are most effec-
tive when used together with a partner drug that possesses a 
longer half-life (e.g., mefl oquine), thus the rationale behind 
the combination. The effectiveness of artemisinin against 
MDR malaria is always cited as 1 of its advantageous 
characteristics (14). Recent evidence of the failure of arte-
sunate–mefl oquine combination therapy on the Thailand–
Cambodia border and of resistance to artemisinin (15,16) 
has raised concerns about the failure of the last effective 
antimalarial drugs. The loss of artemisinins could negative-
ly affect global public health because it would jeopardize 
effective malaria control, leading to increases in illness and 
eventually deaths. Malaria elimination, which has recently 
regained much interest, is also threatened by artemisinin 
failure (17).
The Case for Defi ning XDR Malaria
The emergence of artemisinin resistance creates the 
need to defi ne a new subgroup of drug-resistant malaria, 
XDR malaria. Such a label should be considered because 
it signifi es the potential loss of artemisinin and highlights 
the threat of an expanded malaria-endemic area with poor 
ACT effi cacy, similar to prior global spread of antimalarial 
drug resistance for other chemical classes. From the public 
health viewpoint, this situation must be handled carefully, 
beyond the existing WHO recommendations for malaria 
drug policy revision (18). The Cambodian and the Thai 
NMCPs are implementing special priority control mea-
sures against this high level of drug-resistant malaria. They 
are working together to contain artemisinin-resistant para-
sites; their ambitious goal is to eliminate falciparum ma-
laria from this epicenter of resistance (19). To do so, they 
face a number of challenges, including the lack of a suitable 
alternative antimalarial drug for empiric treatment.
Not all malaria-endemic countries have well-docu-
mented, successive development of resistance to multiple 
drugs of different chemical classes, as has been docu-
mented on the Thailand–Cambodia border. Although ar-
temisinin resistance has not been described outside Asia, 
a situation leading to similar development of extensively 
drug-resistant parasites will likely happen elsewhere. Af-
rica is a primary concern because of its high prevalence 
of malaria. Chloroquine resistance and high-level SP resis-
tance are highly prevalent in parts of Africa such as Kenya 
(20). A possible scenario of concern is the consolidation 
of amodiaquine and SP resistance and/or development 
of a new resistant strain against lumefantrine and/or me-
fl oquine (which is known for its activity correlation with 
lumefantrine in vitro). In recent years, the combination of 
artemether and lumefantrine, or Coartem, was introduced 
in large scale to Africa. High rates of recurrence of P. falci-
parum infection have already been found in Zanzibar after 
Coartem therapy and include several cases of recrudes-
cence associated with lumefantrine-resistant parasites (21). 
Although an ACT containing mefl oquine has never been 
adopted by any African country, the artesunate–mefl oquine 
combination is already common in some African markets. 
Antimalarial drugs that are not used, per national treatment 
guidelines, can be widely available enough, especially in 
the private sector of low-income countries, to induce selec-
tion pressure for resistance or cross-resistance.
After 2 decades of use, the term MDR malaria is not 
the trigger for action it once was. Designating a malaria-
endemic area with artemisinin-resistant falciparum strains 
as an area with XDR malaria will signal an urgent need for 
action, such as ongoing public health attention and priori-
tizing funding and support. A similar sense of complacency 
with regard to MDR TB, the loss of treatment utility, and 
the need to instill urgency into global efforts to prevent and 
treat drug resistance led WHO to establish the term XDR 
TB in 2006 (7).
In most settings, the primary way to control XDR TB 
is to prevent its emergence through optimal treatment of 
drug-susceptible TB (22). Therefore, from a control pro-
gram’s perspective, knowing that XDR TB exists in the 
community does not alter the general Stop TB strategy 
(www.who.int/tb/strategy/en/). However, specifi c determi-
nation of drug resistance is essential for clinical manage-
ment. The cost of treating MDR or XDR TB cases that do 
emerge is high and requires extra public health resources, 
including a greatly expanded and upgraded laboratory net-
work and access to specialized physician and nursing care. 
Similarly, the development of any drug resistance in malar-
ia introduces an additional set of fi nancial and operational 
challenges for a malaria control program.
For clinicians dealing with sporadic malaria cases out-
side a disease-endemic area, the term XDR malaria also 
deserves special attention. For example, Coartem is often 
prescribed for drug-resistant malaria. Given its potential-
ly limited effi cacy against falciparum malaria in western 
Cambodia (23) and activity correlation between mefl oquine 
and lumefantrine in vitro, its prescription for patients from 
XDR malaria areas will need to be reconsidered.
Introducing the term XDR malaria in association 
with artemisinin resistance should not discourage the de-
ployment of ACTs in Africa, where it is hoped that these 
regimens will contribute to substantial reduction of malaria 
incidence and deaths. However, it will help alert countries 
that have recently adopted ACTs that resistance is pos-
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sible and that vigilance in monitoring for resistance and 
reinforcement of rational drug use are essential. Control 
programs sometimes strongly strive for universal access 
to ACTs but are unable to regulate or ensure their rational 
use, especially when ACTs are widely available in the pri-
vate and informal healthcare sectors (24). Such a balance of 
concerns should be redressed.
Conclusions
For TB and malaria control, providing specifi c labels 
to drug-resistant strains benefi ts individual patient care and 
public health. For TB, agreement on specifi c defi nitions for 
MDR and XDR TB facilitated epidemiologic assessment, 
program planning, laboratory capacity enhancement, and 
development of standardized treatment regimens. For ma-
laria, the rapid increase in the prevalence of drug-resistant 
malaria globally and emerging artemisinin resistance in 
Southeast Asia show that the time to defi ne and combat 
XDR malaria has arrived.
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Article Title
Extensive Drug Resistance in Malaria and Tuberculosis
CME Questions
Activity Evaluation
1. You are seeing a couple who recently emigrated 
from Uganda. One of these patients, a 32-year-old 
woman, has a history of active tuberculosis (TB) and 
said she was treated with several drugs for 2 months, 
but she was told they were not working.
According to international consensus, multidrug-
resistant (MDR) TB is defi ned by resistance to at least 
which of the following medications?
A.  Rifampin only
B.  Rifampin and isoniazid
C.  Isoniazid and ethambutol 
D. Ethambutol, pyrazinamide, and rifampin
2. Which of the following statements regarding the 
treatment of this patient with TB is most accurate?
A.  Guidelines in the United States now recommend 
extending 4-drug treatment for TB based on the 
patients' symptoms alone
B.  The World Health Organization recommends directly 
observed therapy (DOT) for treatment with rifampin
C.  Previous TB treatment does not affect her risk of 
harboring resistant organisms
D. TB treatment should be changed when there is no 
clinical improvement after 2 weeks
3. The other patient is a 31-year-old man with 
intermittent fever and headache for 3 weeks. He is 
hospitalized, and malaria is diagnosed.
Which of the following general principles regarding 
the treatment of this patient is most accurate?
A.  Multidrug resistance in Plasmodium falciparum is 
defi ned by resistance to more than 2 operational 
antimalarial compounds from 2 different classes
B.  The use of combination antimalarial therapy has not 
improved effi cacy or reduced resistance
C.  The decision to treat MDR malaria is based on 
complicated laboratory data
D. Geography has little impact on the treatment choice of 
malaria
4. Which of the following statements regarding drug-
resistant malaria is most accurate??
A.  The simplest way to monitor the effi cacy of a 
given therapeutic regimen is through molecular 
characterization
B.  There is no known resistance to the combination of 
artesunate and mefl oquine
C.  Artemisinin resistance is now common in Africa
D. Rates of artemisinin-based combination resistance 
need to be monitored in Africa
1. The activity supported the learning objectives. 
Strongly Disagree Strongly Agree 
1 2 3 4 5
2. The material was organized clearly for learning to occur.
Strongly Disagree Strongly Agree
1 2 3 4 5
3. The content learned from this activity will impact my practice.
Strongly Disagree Strongly Agree
1 2 3 4 5
4. The activity was presented objectively and free of commercial bias.
Strongly Disagree Strongly Agree
1 2 3 4 5
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